BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Etakafusp alfa readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Etakafusp alfa\, from ClinicalTrials.gov 
 estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07037758-2478@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20280318
DTEND;VALUE=DATE:20280319
SUMMARY:Etakafusp alfa: Phase 1 readout est. (NCT07037758)
DESCRIPTION:Etakafusp alfa\, phase 1.\nStudy: A Study of Tarlatamab in Comb
 ination With AB248 in Participants With Extensive Stage Small Cell Lung Ca
 ncer (DeLLphi-311)\nEstimated primary completion: 18 March 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/etakafusp-alfa#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07037758
URL:https://assetmemo.bio/drug/etakafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07300475-2478@assetmemo.bio
DTSTAMP:20261121T005716Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Etakafusp alfa: Phase 1 readout est. (NCT07300475)
DESCRIPTION:Etakafusp alfa\, phase 1.\nStudy: Personalized Cancer Vaccine (
 PCV) Strategy in Triple Negative Breast Cancer Patients\nEstimated primary
  completion: 30 September 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/etakafusp-alfa#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07300475
URL:https://assetmemo.bio/drug/etakafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
